Laboratory parameters for treatment-naïve children with conditional TCD velocities who received hydroxyurea treatment
| . | Baseline . | Month 6 . | Month 12 . | Month 24 . | Month 36 . | Month 48 . | Month 60 . | P value∗ . |
|---|---|---|---|---|---|---|---|---|
| No. of children | 57 | 57 | 55 | 52 | 50 | 43 | 36 | |
| Dose, mean ± SD | 20.5 ± 1.1 | 21.2 ± 3.3 | 23.9 ± 5.9 | 25.7 ± 5.8 | 27.0 ± 5.2 | 24.4 ± 5.5 | 25.7 ± 5.7 | <.0001 |
| Hb, g/dL | 7.5 ± 0.9 | 8.4 ± 1.2 | 8.6 ± 1.3 | 8.9 ± 1.5 | 8.9 ± 1.3 | 8.7 ± 1.3 | 8.7 ± 1.3 | <.0001 |
| MCV, fL | 88 ± 7 | 100 ± 8 | 102 ± 9 | 106 ± 10 | 105 ± 10 | 106 ± 10 | 104 ± 10 | <.0001 |
| HbF, % | 15.6 ± 7.3 | 24.7 ± 9.5 | 27.1 ± 10.7 | 30.8 ± 12.9 | 28.4 ± 13.3 | 23.4 ± 12.5 | 27.1 ± 11.8 | <.0001 |
| WBC, × 109/L | 15.6 ± 6.0 | 11.3 ± 3.4 | 9.6 ± 3.4 | 9.0 ± 3.5 | 8.7 ± 2.9 | 9.4 ± 3.6 | 10.7 ± 4.7 | <.0001 |
| ANC, × 109/L | 7.8 ± 2.9 | 5.9 ± 2.4 | 4.7 ± 2.5 | 4.5 ± 2.3 | 4.2 ± 1.9 | 4.8 ± 2.5 | 5.4 ± 2.9 | <.0001 |
| Platelets, × 109/L | 447 ± 154 | 389 ± 152 | 346 ± 168 | 347 ± 163 | 361 ± 167 | 330 ± 145 | 366 ± 174 | .0013 |
| ARC, × 109/L | 222 ± 108 | 167 ± 65 | 156 ± 95 | 176 ± 86 | 136 ± 69 | 128 ± 67 | 150 ± 71 | .0161 |
| ALT, U/L | 21 ± 15 | 24 ± 18 | 27± 11 | 19 ± 12 | 24 ± 18 | 28 ± 16 | 26 ± 12 | .4466 |
| Creatinine, mg/dL | 0.4 ± 0.2 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.5 ± 0.2 | 0.5 ± 0.2 | 0.5 ± 0.2 | 1.0000 |
| . | Baseline . | Month 6 . | Month 12 . | Month 24 . | Month 36 . | Month 48 . | Month 60 . | P value∗ . |
|---|---|---|---|---|---|---|---|---|
| No. of children | 57 | 57 | 55 | 52 | 50 | 43 | 36 | |
| Dose, mean ± SD | 20.5 ± 1.1 | 21.2 ± 3.3 | 23.9 ± 5.9 | 25.7 ± 5.8 | 27.0 ± 5.2 | 24.4 ± 5.5 | 25.7 ± 5.7 | <.0001 |
| Hb, g/dL | 7.5 ± 0.9 | 8.4 ± 1.2 | 8.6 ± 1.3 | 8.9 ± 1.5 | 8.9 ± 1.3 | 8.7 ± 1.3 | 8.7 ± 1.3 | <.0001 |
| MCV, fL | 88 ± 7 | 100 ± 8 | 102 ± 9 | 106 ± 10 | 105 ± 10 | 106 ± 10 | 104 ± 10 | <.0001 |
| HbF, % | 15.6 ± 7.3 | 24.7 ± 9.5 | 27.1 ± 10.7 | 30.8 ± 12.9 | 28.4 ± 13.3 | 23.4 ± 12.5 | 27.1 ± 11.8 | <.0001 |
| WBC, × 109/L | 15.6 ± 6.0 | 11.3 ± 3.4 | 9.6 ± 3.4 | 9.0 ± 3.5 | 8.7 ± 2.9 | 9.4 ± 3.6 | 10.7 ± 4.7 | <.0001 |
| ANC, × 109/L | 7.8 ± 2.9 | 5.9 ± 2.4 | 4.7 ± 2.5 | 4.5 ± 2.3 | 4.2 ± 1.9 | 4.8 ± 2.5 | 5.4 ± 2.9 | <.0001 |
| Platelets, × 109/L | 447 ± 154 | 389 ± 152 | 346 ± 168 | 347 ± 163 | 361 ± 167 | 330 ± 145 | 366 ± 174 | .0013 |
| ARC, × 109/L | 222 ± 108 | 167 ± 65 | 156 ± 95 | 176 ± 86 | 136 ± 69 | 128 ± 67 | 150 ± 71 | .0161 |
| ALT, U/L | 21 ± 15 | 24 ± 18 | 27± 11 | 19 ± 12 | 24 ± 18 | 28 ± 16 | 26 ± 12 | .4466 |
| Creatinine, mg/dL | 0.4 ± 0.2 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.5 ± 0.2 | 0.5 ± 0.2 | 0.5 ± 0.2 | 1.0000 |
A total of 57 children who were not on treatment at the time of initial TCD screening received hydroxyurea per protocol for an average duration of 56 ± 17 months. Percent HbF is calculated as HbF/(HbF + HbS).
ALT, alanine transferase; ANC, absolute neutrophil count; ARC, absolute reticulocyte count; HbF, fetal hemoglobin; HbS, sickle hemoglobin; MCV, mean corpuscular volume; SD, standard deviation; WBC, white blood cell.
P values compare laboratory parameters at months 0 and 24.